Atheroma; HeartGARP-CSNCT07384910
Assessment of GARP Expression in Acute and Chronic Coronary Syndrome
A study testing Arterial blood sample in people with Atheroma; Heart, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atheroma; Heart
- What is being tested?
- Arterial blood sample
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- 1 siteBelgium
- Study dates
- Feb 2026to Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Older than 18 years
- Able to give informed consent
- Undergoing coronary angiography.
Who cannot join
- Patients younger than 18 years
- Unable to give consent
- Pregnancy
- Dialysis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site
Cliniques Universitaires Saint-Luc
Brussels, 1200
Louis Charki, Medical Degree, +3224362014, louis.charki@uclouvain.be
Christophe Beauloye, Medical Degree
About this study
Official title: Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
- Conditions
- Atheroma; Heart
- Being tested
- Arterial blood sample
- Keywords
- Atheroma, Atherosclerosis, GARP, LRRC32
- Medical subject headings
- Coronary Artery Disease, Plaque, Atherosclerotic, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arterial blood sampleBiological
An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place.
| Study group | Role | What they receive |
|---|---|---|
| Acute coronary syndrome | Experimental | This arm includes patients undergoing coronary angiography with a final diagnostic of acute coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. Receives: Biological: Arterial blood sample |
| Chronic coronary syndrome | Experimental | This arm includes patients undergoing coronary angiography with a final diagnostic of chronic coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. Receives: Biological: Arterial blood sample |
| Control | Experimental | This arm includes patients undergoing coronary angiography with a final diagnostic of non significant coronary disease. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. Receives: Biological: Arterial blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Platelet GARP expression
The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.
Measured: Throughout the entire study, approximately during 2 years
Secondary outcomes (1)
Inflammatory profile
The inflammatory cytokines (IL-1, IL-6, TNF,...) profile will be determined by multiplex and compared between arms.
Measured: Throughout the entire study, approximately during 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study startFeb 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atheroma; HeartStudies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Responsible party
- Sponsor
- Investigators
- Christophe Beauloye, Medical Degree, Principal investigator, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384910
- Sponsor's protocol ID
- GARP-CS
- Acronym
- GARP-CS
- Status last verified
- Feb 2026
- First submitted
- 26 Jan 2026
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome
- ClinicalTrials.gov ID
- NCT07384910
- Acronym / sponsor ID
- GARP-CS / GARP-CS
- Conditions
- Atheroma; Heart
- Keywords
- Atheroma, Atherosclerosis, GARP, LRRC32
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Study start
- Feb 2026 (estimated)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Acute coronary syndrome | Experimental | Biological: Arterial blood sampleThis arm includes patients undergoing coronary angiography with a final diagnostic of acute coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. |
| Chronic coronary syndrome | Experimental | Biological: Arterial blood sampleThis arm includes patients undergoing coronary angiography with a final diagnostic of chronic coronary syndrome. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. |
| Control | Experimental | Biological: Arterial blood sampleThis arm includes patients undergoing coronary angiography with a final diagnostic of non significant coronary disease. The intervention administered is an arterial blood sample from the sheath at the beginning of the examination. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Older than 18 years
- Able to give informed consent
- Undergoing coronary angiography.
Key exclusion criteria (4 listed)
- Patients younger than 18 years
- Unable to give consent
- Pregnancy
- Dialysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arterial blood sampleAn arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place. | Biological | Acute coronary syndrome, Chronic coronary syndrome, Control |
Primary outcome
Platelet GARP expression
Time frame: Throughout the entire study, approximately during 2 years
The platelet GARP expression profile will be assessed and compared between arms using flow cytometry.
1 secondary outcome
Inflammatory profile
Time frame: Throughout the entire study, approximately during 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Atheroma; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Christophe Beauloye, Medical Degree principal investigator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Arterial blood sample in people with Atheroma; Heart, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Louis Charki, Medical Degree (+3224362014, louis.charki@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Platelet GARP expression (time frame: Throughout the entire study, approximately during 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.